Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

TCRX

Tscan Therapeutics Inc

Apr 19 • 04:00PM ET

6.82

Dollar change -0.10
Percentage change -1.45	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI SURI VXF DWAS IWC AVSC BMED DFUS DFAU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.89	Insider Own	16.42%	Shs Outstand	47.83M	Perf Week	-12.00%
Market Cap	297.56M	Forward P/E	-	EPS next Y	-1.14	Insider Trans	0.48%	Shs Float	36.46M	Perf Month	-2.71%
Income	-89.22M	PEG	-	EPS next Q	-0.26	Inst Own	67.89%	Short Float	0.60%	Perf Quarter	26.53%
Sales	21.05M	P/S	14.14	EPS this Y	23.24%	Inst Trans	-0.43%	Short Ratio	1.15	Perf Half Y	87.36%
Book/sh	3.15	P/B	2.16	EPS next Y	-9.43%	ROA	-37.87%	Short Interest	0.22M	Perf Year	224.76%
Cash/sh	4.40	P/C	1.55	EPS next 5Y	-	ROE	-71.29%	52W Range	1.62 - 9.00	Perf YTD	16.98%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-25.53%	ROI	-37.69%	52W High	-24.22%	Beta	0.96
Dividend TTM	-	Quick Ratio	6.51	Sales past 5Y	230.91%	Gross Margin	74.53%	52W Low	320.99%	ATR (14)	0.54
Dividend Ex-Date	-	Current Ratio	6.51	EPS Y/Y TTM	31.37%	Oper. Margin	-444.00%	RSI (14)	43.73	Volatility	7.63% 7.62%
Employees	154	Debt/Eq	0.61	Sales Y/Y TTM	55.52%	Profit Margin	-423.86%	Recom	1.20	Target Price	11.00
Option/Short	No / Yes	LT Debt/Eq	0.57	EPS Q/Q	73.41%	Payout	-	Rel Volume	1.47	Prev Close	6.92
Sales Surprise	108.77%	EPS Surprise	27.39%	Sales Q/Q	132.99%	Earnings	Mar 06 BMO	Avg Volume	190.20K	Price	6.82
SMA20	-8.95%	SMA50	-2.29%	SMA200	48.36%	Trades		Volume	278,857	Change	-1.45%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-22-23	Initiated	Wedbush	Outperform	$8

Apr-19-24 10:05AM	TScan Therapeutics Announces Closing of Upsized Public Offering (GlobeNewswire)
Apr-17-24 12:30AM	TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering (GlobeNewswire) -5.33%
Apr-16-24 04:25PM	TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering (GlobeNewswire) -7.28%
04:01PM	TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities (GlobeNewswire)
Apr-08-24 08:00AM	TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer (GlobeNewswire)
07:00AM	Loading…
Apr-02-24 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -10.11%
Mar-17-24 02:58PM	Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With (InvestorPlace)
Mar-07-24 01:44PM	TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline (GuruFocus.com)
Mar-06-24 01:51PM	TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 07:00AM	TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-26-24 07:00AM	TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-19-24 05:49AM	TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar? (Zacks)
Feb-14-24 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
07:00AM	Loading…
Feb-06-24 07:00AM	TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development (GlobeNewswire) +6.67%
Jan-29-24 07:00AM	TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer (GlobeNewswire)
Jan-18-24 07:00AM	TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire) -9.62%
Jan-04-24 07:00AM	TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress (GlobeNewswire)
Dec-09-23 12:00PM	TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-07-23 07:00AM	TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations (GlobeNewswire)
Dec-06-23 08:50AM	Recent Price Trend in TScan Therapeutics, Inc. (TCRX) is Your Friend, Here's Why (Zacks)
Dec-04-23 04:05PM	TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition (GlobeNewswire) -5.56%
07:00AM	TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer (GlobeNewswire)
Dec-01-23 09:55AM	Does TScan Therapeutics, Inc. (TCRX) Have the Potential to Rally 62.33% as Wall Street Analysts Expect? (Zacks)
Nov-30-23 07:00AM	TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years (GlobeNewswire) +12.98%
Nov-27-23 12:00PM	TScan Therapeutics, Inc. (TCRX) is a Great Momentum Stock: Should You Buy? (Zacks)
Nov-20-23 08:50AM	TScan Therapeutics, Inc. (TCRX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -13.83%
Nov-15-23 12:00PM	What Makes TScan Therapeutics, Inc. (TCRX) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 125% Upside in TScan Therapeutics, Inc. (TCRX): Here's What You Should Know (Zacks)
08:25AM	Loading…
Nov-09-23 08:25AM	TScan Therapeutics Inc (TCRX) Reports Q3 2023 Financial Results and Corporate Updates (GuruFocus.com)
07:00AM	TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-23 07:00AM	TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting (GlobeNewswire) +11.03%
Nov-02-23 09:05AM	TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) +7.73%
Oct-12-23 12:00PM	TScan Therapeutics, Inc. (TCRX) Upgraded to Strong Buy: Here's Why (Zacks)
Sep-27-23 09:06AM	TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-12-23 08:00AM	Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors (GlobeNewswire)
Sep-05-23 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-29-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME (GlobeNewswire) +10.96%
Aug-16-23 12:00PM	TScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-10-23 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-13-23 07:25AM	Shareholders in TScan Therapeutics (NASDAQ:TCRX) are in the red if they invested a year ago (Simply Wall St.)
Jun-29-23 07:00AM	TScan Therapeutics Announces Transition of Chief Financial Officer (GlobeNewswire)
Jun-15-23 07:42AM	Favourable Signals For TScan Therapeutics: Numerous Insiders Acquired Stock \ (Simply Wall St.)
Jun-06-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors (GlobeNewswire)
Jun-01-23 04:10PM	TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
04:05PM	TScan Therapeutics Announces Closing of Public Offering (GlobeNewswire)
07:00AM	TScan Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-26-23 12:37AM	TScan Therapeutics Announces Pricing of $140 Million Public Offering (GlobeNewswire) +31.28%
May-25-23 04:06PM	TScan Therapeutics Announces Launch of Proposed Public Offering (GlobeNewswire)
May-24-23 04:13PM	TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors (GlobeNewswire)
May-17-23 04:35PM	TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients (Benzinga) -10.53%
07:00AM	TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting (GlobeNewswire)
May-11-23 07:33AM	Institutional investors control 30% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 112% (Simply Wall St.) -7.22%
May-10-23 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +42.65%
07:00AM	TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 01:29PM	Why Are TScan Therapeutics Shares Are Shooting Higher Today (Benzinga) +51.14%
09:00AM	Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohns Disease (GlobeNewswire)
May-02-23 04:42PM	TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire) +26.22%
Apr-10-23 07:00AM	TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors (GlobeNewswire)
Mar-31-23 08:00AM	TScan Therapeutics Announces CEO Transition (GlobeNewswire) -18.29%
Mar-14-23 07:00AM	TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies (GlobeNewswire)
Mar-13-23 04:05PM	TScan Therapeutics to Participate in the Barclays Global Healthcare Conference (GlobeNewswire) -13.31%
Mar-10-23 05:12AM	TScan Therapeutics Full Year 2022 Earnings: Misses Expectations (Simply Wall St.)
Mar-08-23 07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones (GlobeNewswire)
Mar-01-23 07:00AM	TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire) +6.78%
Feb-21-23 07:00AM	TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Jan-23-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors (GlobeNewswire)
Jan-20-23 05:35AM	Shareholders in TScan Therapeutics (NASDAQ:TCRX) are in the red if they invested a year ago (Simply Wall St.)
Jan-05-23 07:00AM	TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress (GlobeNewswire)
Dec-12-22 07:00AM	TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022 (GlobeNewswire)
Dec-09-22 06:09AM	A number of insiders bought TScan Therapeutics, Inc. (NASDAQ:TCRX) stock last year, which is great news for shareholders (Simply Wall St.)
Dec-01-22 08:00AM	TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe (GlobeNewswire)
Nov-22-22 07:00AM	TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-11-22 07:00AM	TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) +7.81%
Nov-09-22 07:00AM	TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 07:00AM	TScan Therapeutics Announces Upcoming Virtual Investor Event (GlobeNewswire)
Nov-03-22 09:34AM	TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) +8.65%
Oct-05-22 08:33AM	TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-28-22 09:21AM	Chinese Billionaire Zhang Lei is Selling These 10 Stocks (Insider Monkey)
Sep-22-22 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -8.28%
Sep-12-22 07:00AM	TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures (GlobeNewswire)
Sep-07-22 07:00AM	TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire) +12.12%
Aug-13-22 08:14AM	TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates (Simply Wall St.)
Aug-12-22 06:08AM	New Forecasts: Here's What Analysts Think The Future Holds For TScan Therapeutics, Inc. (NASDAQ:TCRX) (Simply Wall St.) -5.41%
Aug-10-22 07:00AM	TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress (GlobeNewswire) -9.88%
Aug-05-22 11:58AM	Shareholders in TScan Therapeutics (NASDAQ:TCRX) are in the red if they invested a year ago (Simply Wall St.)
Aug-03-22 07:00AM	TScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-11-22 07:00AM	TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology (GlobeNewswire)
Jul-07-22 07:00AM	TScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officer (GlobeNewswire)
Jul-06-22 08:28AM	Is TScan Therapeutics (NASDAQ:TCRX) In A Good Position To Invest In Growth? (Simply Wall St.)
Jun-22-22 07:00AM	TScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium (GlobeNewswire) +5.28%
Jun-02-22 07:00AM	TScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-31-22 07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies (GlobeNewswire)
May-22-22 08:03AM	Insider Buying: The TScan Therapeutics, Inc. (NASDAQ:TCRX) President Just Bought 17% More Shares (Simply Wall St.)
May-19-22 07:00AM	TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting (GlobeNewswire) -14.80%
May-17-22 07:00AM	TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire) +15.94%
May-12-22 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual Meeting (GlobeNewswire)
May-09-22 07:00AM	TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones (GlobeNewswire) -8.33%

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BARBERICH TIMOTHY J	Director	Dec 19 '23	Buy	4.97	317	1,575	67,027	Dec 21 05:00 PM
BARBERICH TIMOTHY J	Director	Dec 18 '23	Buy	4.89	28,830	140,881	66,710	Dec 21 05:00 PM
Klencke Barbara	Director	Dec 14 '23	Buy	5.08	5,000	25,400	30,000	Dec 18 06:01 PM
BARBERICH TIMOTHY J	Director	Jun 02 '23	Buy	2.63	37,880	99,564	37,880	Jun 06 07:53 PM
Lynx1 Capital Management LP	10% Owner	May 31 '23	Sale	2.52	25,400	63,952	5,224,600	Jun 02 05:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TCRX

Tscan Therapeutics Inc

Upgrade your FINVIZ experience